Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Abstract:
On Thursday, October 2, 2008, Dr. Tamarkin will be a featured speaker from 10:30-12:30 in the medicine and biology track at NanoTx08. His speech will focus on the recent Phase I CYT-6091 cancer patient trial in which the Company's gold nanomedicine was used to deliver a potent, but toxic, anti-cancer therapeutic to solid tumors. Such tumor targeting is best accomplished by avoiding uptake by the immune system and by limiting the biodistribution of the drug to the tumor. CYT-6091 accomplishes this by binding the potent, but toxic molecule TNF to the surface of PEGylated colloidal gold nanoparticles. TNF's toxicity is so severe that its clinical use is limited to isolated limb perfusion (ILP), where 1 mg of TNF followed by doxorubicin results in a 60-85% local response rate. In the completed CYT-6091 Phase I dose escalation clinical trial a similar dose of TNF was injected systemically. The treatment was well-tolerated, showing no dose limiting toxicity, and patient biopsies taken 24-hours after treatment showed gold nanoparticles in patient tumors. Multiple Phase II combination trials are planned.

The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Rockville, MD | Posted on September 30th, 2008

####

About CytImmune Sciences, Inc.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.

Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.

For more information, please click here

Contacts:
CytImmune Sciences
9640 Medical Center Drive
Rockville, MD 20850
Phone: (240)-864-2796
Fax: (301) 315-2438

Copyright © CytImmune Sciences, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project